A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Advanced Solid Tumors
DRUG: HGS1029
To assess the safety and dose-limiting toxicity of HGS1029 administered weekly X 3, repeated every 4 weeks, throughout the study
Determination of pharmacokinetic profile; evaluation of biomarkers; evaluation of possible anti-tumor activity, throughout the study
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.